The Essential and Optimal Analgesic and Anti-Inflammatory Medicines for Athletes at the Olympic Games.

IF 4.1 2区 医学 Q1 SPORT SCIENCES Sports Medicine - Open Pub Date : 2024-07-19 DOI:10.1186/s40798-024-00743-3
Mark Stuart, Mohammed Farooq, Trudy Thomas, Nada Mohamed-Ali, Mohammed Al-Maadheed, Vidya Mohamed-Ali
{"title":"The Essential and Optimal Analgesic and Anti-Inflammatory Medicines for Athletes at the Olympic Games.","authors":"Mark Stuart, Mohammed Farooq, Trudy Thomas, Nada Mohamed-Ali, Mohammed Al-Maadheed, Vidya Mohamed-Ali","doi":"10.1186/s40798-024-00743-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In 2019, the International Olympic Committee published the first Olympic and Paralympic Model Formulary (OPF), which defined the standardised set of medications required at every Olympic and Paralympic Games for the treatment of athletes. This study aimed to test the OPF to determine whether it meets the clinical needs of the athlete population with respect to medications used for pain and/or inflammation (PI), and to present a revised set of essential PI medications for the OPF based on prevalence of athlete use. Medication-use data of athletes at the Tokyo 2020 and Beijing 2022 Olympic Games (n = 6155) from three sources were used to establish prevalence of PI medicine use and to revise the OPF: (i) doping control forms, (ii) pharmacy dispensing reports, and (iii) injection declaration forms. This revised list was further validated through (iv) medication importation declarations by teams (n = 156), and (v) survey of team physicians (n = 382).</p><p><strong>Results: </strong>Overall prevalence of PI medication use was 36.7%, with higher use by female athletes (female: 44.1%; male: 30.0%; p < 0.001), with non-steroidal anti-inflammatory drugs being the most used class (27%). Use of medications with safety risks were identified, including nimesulide, piroxicam and metamizole. A revised list of 48 PI medications was recommended for the OPF.</p><p><strong>Conclusion: </strong>The research led to a revised set of essential medications for the treatment of pain and inflammation to be available for athletes at the Olympic Games, which would lead to a 7% improvement in the numbers of athletes who could have their exact PI medication requirements met by the OPF.</p>","PeriodicalId":21788,"journal":{"name":"Sports Medicine - Open","volume":"10 1","pages":"80"},"PeriodicalIF":4.1000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sports Medicine - Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40798-024-00743-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SPORT SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In 2019, the International Olympic Committee published the first Olympic and Paralympic Model Formulary (OPF), which defined the standardised set of medications required at every Olympic and Paralympic Games for the treatment of athletes. This study aimed to test the OPF to determine whether it meets the clinical needs of the athlete population with respect to medications used for pain and/or inflammation (PI), and to present a revised set of essential PI medications for the OPF based on prevalence of athlete use. Medication-use data of athletes at the Tokyo 2020 and Beijing 2022 Olympic Games (n = 6155) from three sources were used to establish prevalence of PI medicine use and to revise the OPF: (i) doping control forms, (ii) pharmacy dispensing reports, and (iii) injection declaration forms. This revised list was further validated through (iv) medication importation declarations by teams (n = 156), and (v) survey of team physicians (n = 382).

Results: Overall prevalence of PI medication use was 36.7%, with higher use by female athletes (female: 44.1%; male: 30.0%; p < 0.001), with non-steroidal anti-inflammatory drugs being the most used class (27%). Use of medications with safety risks were identified, including nimesulide, piroxicam and metamizole. A revised list of 48 PI medications was recommended for the OPF.

Conclusion: The research led to a revised set of essential medications for the treatment of pain and inflammation to be available for athletes at the Olympic Games, which would lead to a 7% improvement in the numbers of athletes who could have their exact PI medication requirements met by the OPF.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
奥运会运动员必备和最佳镇痛消炎药。
背景:2019年,国际奥委会发布了首部《奥运会和残奥会示范处方集》(OPF),该处方集定义了每届奥运会和残奥会上运动员治疗所需的标准化药物集。本研究旨在对 OPF 进行测试,以确定其是否满足运动员人群对疼痛和/或炎症(PI)用药的临床需求,并根据运动员用药的普遍程度,提出一套 OPF 的 PI 必备药物修订版。2020 年东京奥运会和 2022 年北京奥运会运动员(n = 6155)的用药数据来自以下三个来源,用于确定 PI 药物的普遍使用情况并修订 OPF:(i) 兴奋剂检查表;(ii) 药房配药报告;(iii) 注射申报表。修订后的清单通过(iv) 运动队的药物进口申报(n = 156)和(v) 运动队医生调查(n = 382)得到进一步验证:结果:PI 药物使用的总体流行率为 36.7%,女性运动员的使用率更高(女性:44.1%;男性:30.0%;P 结论:研究得出了一套经修订的 PI 药物清单:通过研究,修订了一套治疗疼痛和炎症的基本药物,供奥运会运动员使用,这将使 OPF 能够满足运动员确切的 PI 药物需求的运动员人数增加 7%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Sports Medicine - Open
Sports Medicine - Open SPORT SCIENCES-
CiteScore
7.00
自引率
4.30%
发文量
142
审稿时长
13 weeks
期刊最新文献
Handgrip Strength has Declined Among Adults, Particularly Males, from Shanghai Since 2000. Sleeping Beauty? A Prospective Study on the Prevalence of Sleep Problems and Their Potential Determinants in Professional Dancers. Correction: Sex Differences in Performance and Performance-Determining Factors in the Olympic Winter Endurance Sports. Critical Fluctuations as an Early Warning Signal of Sports Injuries? A Proof of Concept Using Football Monitoring Data. The Use of Extended Reality Technologies in Sport Perceptual-Cognitive Skill Research: A Systematic Scoping Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1